UK regulators have approved a prostate cancer drug for terminally ill patients that can halt the disease for a year.
The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Pluvicto, which could delay the progression of the disease by more than a year.
Cancer experts said it was a “major clinical breakthrough”, giving new hope to men with metastatic disease.